Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2016
Price :
$35
*
At a glance
- Drugs Gevokizumab (Primary)
- Indications Pyoderma gangrenosum
- Focus Registrational; Therapeutic Use
- Sponsors XOMA
- 25 Apr 2016 Status changed from recruiting to discontinued.
- 25 Apr 2016 Status changed from recruiting to discontinued.
- 10 Apr 2014 New trial record